Clinical trials show that semaglutide's weight loss benefits increase with dose, but the relationship is not linear and plateaus vary by individual
GLP-1s and Lean Mass: What the Research Shows Glucagon-like peptide-1 (GLP-1) receptor agonists have been making headlines for their dual role in managing type 2 diabetes and facilitating weight loss
Sorry, but its hard for me to see how a giant burrito can be GLP 1 friendly And I eat them very regularly - this isnt an anti-Chipotle comment
Myth 2: Natural means its safe The truth: Just because something is natural doesnt mean its safe
The average reduction in apnea events per hour dropped from 28 to 12moving many patients from severe to mild-moderate categories
Our Research Lead examined anonymized platform data from: 5,864 US adults using tirzepatide (Mounjaro or Zepbound) 4,456 US adults using semaglutide (Ozempic or Wegovy) Inclusion criteria: Active GLP-1 therapy with weekly injections Minimum 12-week tracking duration Adherence threshold: 1 injection log and 1 weight entry per week No weight entries outside physiological bounds (30300 kg) or with weekly changes exceeding 5% Primary outcome: Percentage body weight change from baseline, calculated as [(current weight baseline weight) / baseline weight] 100 , where negative values indicate weight loss Data collection period: Data were collected from all available platform records through January 2026, representing naturalistic use patterns without researcher intervention
